Neurosarcoidosis following Immune Checkpoint Inhibition

Area of Science:

• Oncology
• Immunology
• Neurology

Background:

• Immune checkpoint inhibitors (ICIs) like nivolumab and ipilimumab enhance anti-tumor immunity.
• However, ICIs can induce immune-related adverse events (irAEs) due to immune system stimulation.
• Neurologic irAEs are rare but serious, posing diagnostic challenges, especially when mimicking CNS metastases.

Observation:

• A patient with metastatic melanoma developed central nervous system (CNS) involvement.
• This CNS manifestation was identified as an exacerbation of sarcoidosis.
• The exacerbation occurred after receiving dual ICI therapy with nivolumab and ipilimumab.

Findings:

• Dual ICI therapy can trigger or exacerbate pre-existing inflammatory conditions like sarcoidosis.
• CNS sarcoidosis can present similarly to CNS metastases, complicating diagnosis and treatment.
• Prompt recognition and management are crucial for patients experiencing neurologic irAEs.

Implications:

• This case underscores the importance of considering irAEs, including sarcoidosis, in patients on ICIs presenting with neurological symptoms.
• Distinguishing irAEs from disease progression (e.g., CNS metastases) is critical for appropriate therapeutic strategies.
• Further research is needed to understand the mechanisms and optimal management of ICI-induced neurologic complications.